Wedbush analyst Laura Chico raised the firm's price target on Ovid Therapeutics to $7 from $5 and keeps an Outperform rating on the shares. The firm highlights multiple updates in the Q4 update, including a $60M private placement, 7mg OV329 data and expansion of the OV329 development program into Tuberous Sclerosis Complex and Infantile Spasms. Separately, KCC2 efforts also remain on track with an upcoming R&D event on April 14 to further describe the platform.
